PP
RLMD icon

PDT Partners’s Relmada Therapeutics RLMD Stock Holding History

PDT Partners’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-16,227
Closed -$75.5K – 732
2024
Q1 		$75.5K Buy
16,227
+1,307
+9% +$6.3K 0.01% 614
2023
Q4 		$61.8K Hold
14,920
– – 0.01% 526
2023
Q3 		$44.8K Sell
14,920
-16,821
-53% -$50K 0.01% 571
2023
Q2 		$78.1K Sell
31,741
-37,621
-54% -$104K 0.01% 537
2023
Q1 		$157K Buy
+69,362
New +$239K 0.02% 512

Other funds holding RLMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

PDT Partners's RLMD Position: Q2 2024 in Review

PDT Partners sold out of Relmada Therapeutics (RLMD) in Q2 2024, closing a stake of 16,227 shares — an estimated $75.5K sold.

PDT Partners first reported a position in RLMD in Q1 2023 and held it in 5 quarters. The position peaked at $157K in Q1 2023. 79 funds tracked by Wall St. Rank hold RLMD as of Q2 2024.

  • PDT Partners reported no remaining Relmada Therapeutics position as of Q2 2024 after selling out during the quarter.
  • PDT Partners sold 16,227 Relmada Therapeutics shares in Q2 2024, an estimated $75.5K.
  • PDT Partners first reported a position in Relmada Therapeutics in Q1 2023 and held it in 5 quarters.
  • PDT Partners's Relmada Therapeutics position peaked at $157K in Q1 2023.
  • 79 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2024.

Based on PDT Partners's 13F filing for Q2 2024, filed 15 Aug 2024.